Emcure will exclusively distribute and promote the Company’s OAD range of products that include well-established brands like Amaryl^® and Cetapin^®.

While SIL will continue to own and manufacture these brands across Sanofi’s plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic solutions for patients who need them across all of India.

There will be no people transition from SIL to Emcure in this arrangement.

Eric Mansion 

General Manager Pharma Southeast Asia and India & MCO Lead, Sanofi

“Over 100 million[i] Indians are living with type 2 diabetes and its complexities in India. Of these, >60% people[ii] are living with uncontrolled blood sugar levels and have a higher risk of developing complications, over a long period of time. Sanofi’s commitment to improving their lives and helping them manage their diabetes better remains unwavering. With Emcure’s wide and deeply penetrated presence across India, we’re confident of tapping into the full growth potential of our best-in-class & industry-leading OADs Amaryl^® and Cetapin^®. This partnership will truly benefit both – the patients who need them and the HCPs who trust and prescribe them.”   

Satish Mehta

Chief Executive Office and Managing Director, Emcure Pharmaceuticals Ltd.

“At Emcure, we are committed to improving patient access to high-quality therapies. With our strong distribution network in India, Sanofi’s trusted oral anti-diabetic medicines will be available to more patients who need them. This collaboration complements our existing diabetes portfolio, creating a comprehensive offering for the millions living with diabetes and supporting better diabetes care across the country.”

The post Emcure Pharmaceuticals Ltd. and Sanofi India Limited Announce Exclusive Distribution Partnership to Broaden Reach of Sanofi’s Oral Anti-diabetic Drugs appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

Bengaluru, February 6, 2025: Emcure Pharmaceuticals Ltd. (BSE:544210, NSE: EMCURE) today announced its unaudited consolidated financial results for the quarter ended December 31^st, 2024.

The quarter saw strong growth led by the International businesses that grew 23% YoY. The Canadian business continues to perform well, achieving a 34% YoY growth and the Mantra subsidiary is now fully integrated. Company’s Rest of the World (RoW) market business grew a robust 40% YoY aided by strong growth in our non-ARV segment. The company continues to see traction in its key focus markets led by its differentiated product portfolio. Emcure’s Domestic business grew by over 12% to ₹ 888 Cr, led by a steady performance in the base business and aided by in-licensed products.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “Emcure witnessed a strong performance in Q3. Our International business is seeing strong performance on back of our differentiated product portfolio. On the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portfolio. Moving forward, we aim to enhance our organic growth and margins through new product launches and operating efficiencies.”

Revenue break-up:

Contd.
Performance Summary (Consolidated)

The post Emcure Pharmaceuticals Announces Strong Q3FY25 with 18% Revenue Growth and 30% Profit After Tax Growth appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

(Strengthens its commitment to advancing cutting edge research in complex drug delivery)

The post Emcure Pharmaceuticals Inaugurates World-class R&D centre in Gujarat appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

Bengaluru, November 7, 2024: Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced its unaudited consolidated financial results for the quarter ended September 30^th, 2024. The company demonstrated strong performance across geographies, achieving robust revenue and profit growth.

The quarter saw strong growth especially in the International businesses that grew 25% YoY and 18% QoQ. The Canadian business continued to perform well, achieving a 51% YoY growth, driven by robust growth in our base business and our subsidiary, Mantra. The Rest of the world market business grew 29% YoY aided by strong growth in both ARV and Non-ARV segment. The company continues to see strong traction in its key focus markets. Europe experienced steady growth of 6%, driven by an increase in our base business. Emcure’s Domestic business grew by over 15% to ₹ 933 Cr, led by a steady performance in our base business and further aided by Sanofi distribution agreement.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “Emcure witnessed a strong performance in Q2. We have made significant investments in both our International and Domestic businesses over the past 2 years and the benefits of these efforts are starting to particularly reflect in the growth of our International business. Our recent inorganic additions – Sanofi partnership in India and Mantra acquisition in Canada – are now fully integrated and our focus is now on deriving both revenue and operational synergies. Moving forward, we aim to enhance the margins by leveraging operating efficiencies, while continuing to drive strong growth in both Indian and International markets through new product launches and market share gains.”

Revenue break-up: 

Performance Summary (Consolidated) 

The post Emcure Pharmaceuticals Announces Strong Q2FY25 with 20% Revenue Growth and 38% Profit After Tax Growth  appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

The market is seeing strong growth primarily driven by a growing population. As per IQVIA, the Indian dermatology market stands at $1.84 Bn (MAT sales July 2024). The Indian consumers are becoming increasingly conscious of skin health, driving the need for both therapeutic and aesthetic skin care products.

Speaking on the future growth of dermatology, CEO and Managing Director of Emcure Pharmaceuticals Limited, Satish Mehta stated, “The dermatology market in India, is experiencing a significant surge in both value and unit consumption. Emcure is well-positioned to cater to the unmet needs of the Indian market. With a dedicated entity, Emcure aims to concentrate on developing and introducing both prescription and consumer dermatology solutions.”

Emcutix will be spearheaded by G. Sathya Narayanan, who brings with him over three decades of extensive experience in the dermatology sector, with his last stint as the Managing Director of Galderma for South Asia (including India). His notable career includes building some of the most iconic brands in prescription, consumer, and aesthetic dermatology.

Commenting on his new role with Emcutix, Sathya Narayanan said, “Emcutix represents a unique opportunity with derma care solutions for healthcare professionals, patients and consumers by developing a differentiated dermatology portfolio. Building on Emcure’s legacy of innovation, I look forward to building a portfolio of products that will make a meaningful difference in skin health in India.”

The post Emcure Pharma Strengthens its Derma Portfolio with the launch of Emcutix Biopharmaceuticals Limited appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.

o   Effective, holistic, science-backed targeted solutions for symptomatic treatment

o   Convenient to use and carry to keep their health in control

Bengaluru, September 05, 2024: Emcure Pharmaceuticals  Ltd., a leading Indian pharma company with a strong focus on women’s healthcare segment, announces the launch of Arth, a unique range aimed at supporting women through their menopausal journey. The products address the challenges faced by women during menopause, combining scientific research with an understanding of women’s health needs. Arth holistically caters to physical, emotional, and mental well-being of women during this transition.

Menopause is a natural phase in a woman’s life, often accompanied by a variety of physical and psychological symptoms. Perimenopause can last up to 10 years with varying degree of multiple symptoms and women can experience over 30 symptoms^[1] affecting their day-to-day activities. An Emcure study revealed that 96% of woman experience menopausal symptoms during this phase affecting their day-to-day lives, yet many refrain from seeking treatment due to lack of awareness. The Arth range aims to empower women to embrace this phase with good health, minus the judgement associated with it. Arth has been carefully curated to address multiple symptoms faced in the menopausal journey. Some of the SKUs developed as part of this initial launch are the  multi symptom capsules with the goodness of chasteberry, tender breast relief capsules, tablets for bone health & Brahmi capsules for brain fog.

Instead of taking a preachy and conventional route to spread awareness on the subject, the brand will be turning to popular stand up comedians to throw some light on the subject in a light hearted way.

Speaking on the launch, Ms. Namita Thapar, Whole-time Director of Emcure Pharmaceuticals Ltd., said, “At Emcure, we understand the unique challenges that come with this phase of life and are committed to providing comprehensive and effective solutions that empower women to sail through this phase smoothly. With Arth, our focus is to raise awareness and increase access with affordable products to help women navigate menopause with good health and self-strength.”

The product range is meticulously developed to alleviate common menopause symptoms such as hot flashes, night sweats, mood swings, and vaginal dryness to enable a woman transition through the critical juncture of her natural cycle in a light hearted yet thoughtful way.

The post Emcure Pharmaceuticals launches Arth: Comprehensive Solution for Menopause Wellness in India appeared first on newsmantra.in l Latest news on Politics, World, Bollywood, Sports, Delhi, Jammu & Kashmir, Trending news | News Mantra.